Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +47.43%
#3 Pons Pons +45.47%
#4 Non-Playable Coin Non-Playable Coin +27.80%
#5 StonkBroker StonkBroker +27.01%
#6 ApeX ApeX +25.69%
#7 Kinetiq Kinetiq +25.58%
#8 Pudgy Penguins Pudgy Penguins +21.53%
#9 OriginTrail OriginTrail +19.79%
#10 Grass Grass +19.50%
Coin of the day
Smilek to the Bank Smilek to the Bank
Settings
Language
ENGLISH
Currency
USD
Theme
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Rank in Stocks #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Share Price
$2.72
Last synced: 2023-10-19
Market Cap
$111.47M
Change (1 day)
-0.73%
Change (1 year)
0.00%
Country
US
Trade Talaris Therapeutics, Inc. (TALS)

Category

Healthcare
Earnings for Talaris Therapeutics, Inc. (TALS)
Earnings in 2026 TTM: 0
According to Talaris Therapeutics, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Talaris Therapeutics, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH